

Special Issue

Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy

Message from the Guest Editors

Cancer immunotherapy, such as immune checkpoint blockade, is effective against human cancer. However, only a subset of patients benefit from this novel therapy. It is, therefore, important to explore the mechanism behind this phenomenon. Recent evidence suggest that cancer cells may alter the epigenetic machinery, that controls RNA expression, for instance by DNA methylation and histon modifications, to evade the immune attack. In this special issue, we invite researchers to submit original research articles or reviews to uncover how targeting the epigenetic machinery can enhance cancer immunotherapy in human cancer.

Guest Editors

Prof. Dr. Michael Chan

Department of Biomedical Sciences, National Chung Cheng University,
Chia Yi, Taiwan

Dr. Peter J. K. Kuppen

Department of Surgery, Leiden University Medical Center, 2333 ZA
Leiden, The Netherlands

Deadline for manuscript submissions

closed (25 December 2020)



Epigenomes

an Open Access Journal
by MDPI

Impact Factor 4.1
CiteScore 5.3
Indexed in PubMed



mdpi.com/si/39296

Epigenomes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
epigenomes@mdpi.com

[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)





Epigenomes

an Open Access Journal
by MDPI

Impact Factor 4.1
CiteScore 5.3
Indexed in PubMed



[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)



About the Journal

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25.5 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the second half of 2025).